Functional and effective brain connectivity for discrimination between Alzheimer’s patients and healthy individuals: A study on resting state EEG rhythms

Publication date: Available online 22 October 2016
Source:Clinical Neurophysiology
Author(s): Katarzyna J. Blinowska, Franciszek Rakowski, Maciej Kaminski, Fabrizio De Vico Fallani, Claudio Del Percio, Roberta Lizi, Claudio Babiloni
[Objective]This exploratory study provided a proof of concept of a new procedure using multivariate electroencephalographic (EEG) topographic markers of cortical connectivity to discriminate normal elderly (Nold) and Alzheimer's disease (AD) individuals.[Method]The new procedure was tested on an existing database formed by resting state eyes-closed EEG data (19 exploring electrodes of 10-20 system referenced to linked-ear reference electrodes) recorded in 42 AD patients with dementia (age: 65.9 years ± 8.5 standard deviation, SD) and 42 Nold non-consanguineous caregivers (age: 70.6 years ± 8.5 SD). In this procedure, spectral EEG coherence estimated reciprocal functional connectivity while non-normalized directed transfer function (NDTF) estimated effective connectivity. Principal component analysis and computation of Mahalanobis distance integrated and combined these EEG topographic markers of cortical connectivity. The area under receiver operating curve (AUC) indexed the classification accuracy.[Results]A good classification of Nold and AD individuals was obtained combining the EEG markers derived from NDTF and coherence (AUC=86%, sensitivity=0.85, specificity=0.70).[Conclusion]These encouraging results motivate a cross-validation study of the new procedure in age- and education-matched Nold, stable and progressing mild cognitive impairment individuals, and de novo AD patients with dementia.[Significance]If cross-validated, the new procedure will provide cheap, broadly available, repeatable over time, and entirely non-invasive EEG topographic markers reflecting abnormal cortical connectivity in AD patients diagnosed by direct or indirect measurement of cerebral amyloid β and hyperphosphorylated tau peptides.



http://ift.tt/2eFNwJL


http://ift.tt/2eu6o3o


http://ift.tt/2dznxTp


http://ift.tt/2eGiUZz


http://ift.tt/2f4utwQ


http://ift.tt/2dZIPKZ


http://ift.tt/2eFVXVl


http://ift.tt/2dZLHqV


http://ift.tt/2evKwjV


http://ift.tt/2dLkPgD


http://ift.tt/2dyd53r


http://ift.tt/2dy8L3W


http://ift.tt/2etrNs2


http://ift.tt/2ecgMcZ


http://ift.tt/2etsJfO


http://ift.tt/2dyepTG


http://ift.tt/2ewJPbu


http://ift.tt/2evTltN


http://ift.tt/2evTVrK


http://ift.tt/2dLtHTy


http://ift.tt/2ezalAs


http://ift.tt/2ewQjr7


http://ift.tt/2evWsSr


http://ift.tt/2dyoAYr


http://ift.tt/2dLye8D


http://ift.tt/2etInI3


http://ift.tt/2eGJnqf


http://ift.tt/2ew6Mdf


http://ift.tt/2ekhyZ4


http://ift.tt/2eGNWAO


http://ift.tt/2eGmEJr